Drug Profile
Lotamilast - Dermavant Sciences
Alternative Names: DMVT 501; E 6005; RVT-501Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Developer Dermavant Sciences; Eisai Co Ltd
- Class Benzoates; Quinazolines; Skin disorder therapies
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 31 Aug 2021 Discontinued - Phase-I for Atopic dermatitis (In children) in USA (Topical) (Dermavant Sciences pipeline, August 2021)
- 31 Aug 2021 Discontinued - Phase-I/II for Atopic dermatitis (In adolescents, In children) in Japan (Topical) (Dermavant Sciences pipeline, August 2021)
- 31 Aug 2021 Discontinued - Phase-II for Atopic dermatitis (In adolescents, In children) in Canada, USA (Topical) (Dermavant Sciences pipeline, August 2021)